New Antiemetic for CINV Launched
Tesaro announced the launch of Varubi (rolapitant) for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Varubi was approved by the Food and Drug Administration (FDA) in September 2015.
The superior efficacy of Varubi was established in three multiple global, randomized, well-controlled, blinded Phase 3 clinical trials. Varubi, when administe
Varubi, a selective and competitive human substance P/neurokinin 1 (NK-1) receptor antagonist, is available as a single dose pack containing two 90mg tablets.
For more information call (844) 483-7276 or visit Varubirx.com.